Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A. Hurvitz(University of California, Los Angeles), Roberto Hegg(Centro de Pesquisas Oncológicas), Wei‐Pang Chung(National Cheng Kung University), Seock‐Ah Im(Seoul National University Hospital), William Jacot(Institut de Recherche en Cancérologie de Montpellier), Vinod Ganju, Joanne Wing Yan Chiu(University of Hong Kong), Binghe Xu(Peking Union Medical College Hospital), Erika Hamilton(Tennessee Oncology), Srinivasan Madhusudan(University of Nottingham), Hiroji Iwata(Aichi Cancer Center), Sevilay Altıntaş(Antwerp University Hospital), Jan‐Willem Henning, Giuseppe Curigliano(European Institute of Oncology), José Manuel Pérez-García(Hospital Quirónsalud Barcelona), Sung‐Bae Kim(University of Ulsan), Vanessa Petry(Instituto do Câncer do Estado de São Paulo), Chiun‐Sheng Huang(National Taiwan University Hospital), Wěi Li(First Hospital of Jilin University), Jean‐Sébastien Frenel(Institut de Cancérologie de l'Ouest), Silvia Antolín(Complexo Hospitalario Universitario A Coruña), Winnie Yeo(Chinese University of Hong Kong), Giampaolo Bianchini(IRCCS Ospedale San Raffaele), Sherene Loi(Peter MacCallum Cancer Centre), Junji Tsurutani(Showa University Hospital), Anton Egorov(Daiichi Sankyo (United States)), Yali Liu(Daiichi Sankyo (United States)), Jillian Cathcart(Daiichi Sankyo (United States)), Shahid Ashfaque(Daiichi Sankyo (United States)), Javier Cortés(Hospital Quirónsalud Barcelona)
Cited by 618Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis